Ardelyx, Inc. (ARDX)
NASDAQ: ARDX · Real-Time Price · USD
5.66
-0.33 (-5.51%)
At close: Mar 12, 2026, 4:00 PM EDT
5.71
+0.05 (0.88%)
Pre-market: Mar 13, 2026, 8:52 AM EDT
Ardelyx Revenue
In the year 2025, Ardelyx had annual revenue of $407.32M with 22.09% growth. Ardelyx had revenue of $125.22M in the quarter ending December 31, 2025, with 7.82% growth.
Revenue (ttm)
$407.32M
Revenue Growth
+22.09%
P/S Ratio
3.41
Revenue / Employee
$832,965
Employees
489
Market Cap
1.39B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 407.32M | 73.71M | 22.09% |
| Dec 31, 2024 | 333.62M | 209.16M | 168.06% |
| Dec 31, 2023 | 124.46M | 72.30M | 138.61% |
| Dec 31, 2022 | 52.16M | 42.06M | 416.57% |
| Dec 31, 2021 | 10.10M | 2.53M | 33.36% |
| Dec 31, 2020 | 7.57M | 2.29M | 43.36% |
| Dec 31, 2019 | 5.28M | 2.67M | 102.57% |
| Dec 31, 2018 | 2.61M | -39.39M | -93.79% |
| Dec 31, 2017 | 42.00M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 24.03M | -7.60M | -24.02% |
| Dec 31, 2014 | 31.62M | 2.70M | 9.32% |
| Dec 31, 2013 | 28.93M | 23.52M | 434.71% |
| Dec 31, 2012 | 5.41M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vir Biotechnology | 68.56M |
| Intellia Therapeutics | 67.67M |
| Nuvation Bio | 62.90M |
| Immatics | 56.67M |
| Generate Biomedicines | 31.89M |
| AtaiBeckley | 3.02M |
ARDX News
- 1 day ago - Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award - GlobeNewsWire
- 3 days ago - Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C - GlobeNewsWire
- 9 days ago - Ardelyx to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 17 days ago - Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions - GlobeNewsWire
- 20 days ago - Why Ardelyx's Offensive Strategy Doesn't Move The Needle - Seeking Alpha
- 20 days ago - Ardelyx: Strong IBSRELA Growth, But Heavy Operational Spend Clouds Profitability - Seeking Alpha
- 21 days ago - Ardelyx Lead Drug Growth Fails To Lift Sentiment, Stock Drops - Benzinga
- 21 days ago - Ardelyx, Inc. (ARDX) Q4 2025 Earnings Call Transcript - Seeking Alpha